Human Mast Cell Activation by *Staphylococcus aureus*: Interleukin-8 and Tumor Necrosis Factor Alpha Release and the Role of Toll-Like Receptor 2 and CD48 Molecules

Claudio M. Rocha-de-Souza, Beata Berent-Maoz, David Mankuta, Allon E. Moses, and Francesca Levi-Schaffer

Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel; Department of Obstetrics and Gynecology, Hadassah University Hospital, Jerusalem, Israel; and Department of Clinical Microbiology and Infectious Diseases, Hadassah University Hospital, Jerusalem, Israel

Received 27 February 2008/Returned for modification 17 April 2008/Accepted 10 July 2008

The ability of *Staphylococcus aureus* to invade and survive within host cells is believed to contribute to its propensity to cause persistent and metastatic infections. In addition, *S. aureus* infections often are associated with atopic diseases such as dermatitis, rhinitis, and asthma. Mast cells, the key cells of allergic diseases, have a pivotal role in innate immunity and have the capacity of phagocytosis, and they can destroy some pathogenic bacteria. However, little is known about the ability of some other bacteria to survive and overcome mast cell phagocytosis. Therefore, we were interested in evaluating the interplay between mast cells and *S. aureus*. In this study, we show that human cord blood-derived mast cells (CBMC) can be infected by pathogenic *S. aureus*. *S. aureus* displayed a high adherence to mast cells as well as invasive and survival abilities within them. However, when infections were performed in the presence of cytochalasin D or when CBMC were preincubated with anti-Toll-like receptor 2 (TLR2) or anti-CD48 antibodies, the invasiveness and the inflammatory response were abrogated, respectively. Furthermore, we observed an increase of TLR2 and CD48 molecules on CBMC after *S. aureus* infection. The infection of CBMC with *S. aureus* also caused the release of tumor necrosis factor alpha (TNF-α) and interleukin-8 (IL-8). Both live and killed *S. aureus* organisms were found to trigger TNF-α and IL-8 release by CBMC in a time-dependent manner. Cumulatively, these findings suggest that *S. aureus* internalizes and survives in mast cells. This may play an important role in infections and in atopic diseases associated with *S. aureus*.

*Staphylococcus aureus*, a gram-positive bacterium colonizing the human skin and nasopharynx, is one of the most important human pathogens, and it causes various superficial, systemic, and nosocomial infections (13). *S. aureus* infections often are followed by the bacterial invasion of the vascular system, leading to bacteremia and sepsis. The ability of *S. aureus* to be internalized by and survive within some host cells, such as endothelial cells, keratinocytes, and epithelial cells, may contribute to the development of persistent or chronic infections and may eventually lead to deeper tissue infections or dissemination (14, 15, 23). In particular, the invasion of vascular endothelial cells is thought to be a critical step in the development of metastatic infections in patients with *S. aureus* bacteremia, since it results in the upregulation of procoagulant activity, the expression of surface adhesion molecules, and the release of proinflammatory cytokines (36, 43). The colonization of human skin by *S. aureus* is also a characteristic feature of several inflammatory skin diseases, which often are followed by tissue invasion and severe cell damage in a fibronectin-binding protein (FnBP)-dependent manner (15, 27). *S. aureus* also can survive engulfment by professional phagocytes such as neutrophils and monocytes. In both of these cell types, *S. aureus* promptly escapes from the endosomes/phagosomes and proliferates within the cytoplasm (44). Furthermore, recent in vitro studies showed that *S. aureus* survived inside macrophages in a metabolically active form that did not affect the viability of these cells until the intracellular environment became suitable for escape. This finding suggests that the ability of *S. aureus* to survive phagocytosis in human macrophages contributes to the dissemination of the infection and may be detrimental to the host (16).

An interesting link has been shown between *S. aureus* and atopic diseases, such as dermatitis, rhinitis, and asthma (5), in which it has been hypothesized that *S. aureus* can exacerbate the immunoglobulin E (IgE)-mediated reactions. For example, studies have shown greater *S. aureus* colonization in the skin of patients with atopic eczema/dermatitis syndrome than in the skin of normal healthy subjects (7, 38). Moreover, in chronic rhinosinusitis, *S. aureus* enterotoxin B shifts the cytokine pattern toward Th2. *S. aureus* enterotoxin B also stimulates the production of interleukin-5 (IL-5) and induces polyclonal IgE production, which might contribute to severe inflammation via the activation of the mast cells (4, 12). IgE antibodies specific to the *S. aureus* superantigens are present in nasal polyp tissue, and their levels correlate with markers of eosinophil activation and recruitment (25).

Mast cells are known key effector cells of IgE-mediated hypersensitivity reactions. In addition, more recently it has been recognized that mast cells, being strategically stationed at
sites exposed to the external environment, such as lung, skin, gastrointestinal, and urinogenital tracts, play a critical role in host defense as cardinal cells of innate immune response against infectious pathogens, including *S. aureus* (17, 28). Indeed, mast cells have been found to bind and internalize granulocyte and granulocyte-monocyte colony-stimulating factor (G-M-CSF), which promotes mast cell maturation and activation (2, 18). Mast cells can recognize and attach to a wide variety of opsonized bacteria. For example, *Salmonella enterica* serovar Typhimurium coated with the iC3b fragment of complement is recognized through complement receptor 3 (CR3) on the mast cell membrane (9). In addition, mast cells express several Fc receptors that are involved in the binding of IgG-coated bacteria (9). Recently, various strains of *Escherichia coli*, *Enterobacter cloacae*, and *Klebsiella pneumoniae* were found to bind avidly to mouse bone marrow-derived mast cells in opsonin-dependent conditions, followed by their internalization within vacuoles (19). In vitro and in vivo studies have shown that mast cells release proinflammatory and chemotactic mediators upon contact with pathogens (2, 19, 21). For example, mast cell-derived tumor necrosis factor alpha (TNF-α) modulates neutrophil influx and bacterial clearance in *Klebsiella pneumoniae* infection (21).

Immune cells, including mast cells, express pattern recognition receptors that recognize pathogen-associated molecular patterns and Toll-like receptors (TLRs), a family of proteins that resemble the antimicrobial Toll proteins of *Drosophila* (26, 35). The involvement of TLRs has been implicated in the host response to several staphylococcal infection models (8, 41). TLR2, expressed on mast cells, has been found to recognize and respond to several pathogen-associated molecular patterns, including peptidoglycan (PGN), lipoproteins, and lipoteichoic acid (37). PGN from *S. aureus* stimulates mast cells in a TLR2-dependent manner to produce TNF-α, IL-4, IL-5, IL-6, and IL-13 (40). The intradermal injection of PGN also stimulates mast cells in a TLR2-dependent manner to produce TNF-α, IL-4, IL-5, IL-6, and IL-13 (40). The intradermal injection of PGN also led to increased vasodilatation and inflammation through the TLR2-dependent activation of mast cells (40). Furthermore, in response to PGN or other TLR2 activators, mast cell degranulation has been attributed a critical role in exacerbating allergic diseases, especially atopic dermatitis (5).

Another important molecule in bacteria-mast cell interaction is CD48, a glycosylphosphatidylinositol-anchored protein (39). The cleavage of CD48 from the mast cell surface with phospholipase C or its neutralization with CD48-specific antibodies prevented subsequent bacterial adherence (22). The engagement of CD48 by FimH-expressing type I fimbriated *Escherichia coli* also was found to trigger TNF-α release by mast cells (22).

In spite of all the aforementioned evidence of an interplay between *S. aureus* and mast cells and of its importance in the dynamics of an allergic disease concomitant to infection, the direct cross-talk between human mast cells and *S. aureus* has not been studied in depth. Therefore, we decided in the present study to analyze the interactions between human cord blood-derived mast cells (CBMC) and *S. aureus*.

We report here that, in vitro, *S. aureus* adheres to, invades, survives in, and stimulates human mast cells under the involvement of CD48 and TLR2.

MATERIALS AND METHODS

**Bacterial culture conditions.** *Staphylococcus aureus* ATCC 25923 and *S. aureus* HUH1, a methicillin-susceptible strain isolated from a patient with a blood-stream infection in the Department of Clinical Microbiology and Infectious Diseases at the Hadassah University Hospital, were used. Bacteria maintained at −70°C in skim milk-glycerol (Difco) were subcultured onto blood agar and incubated at 37°C overnight. A sweep of colonies was inoculated into tryptic soy broth (TSB; Difco) and incubated at 37°C for 24 h. The culture density was estimated by the measurement of the optical density at 650 nm. Bacteria were diluted to achieve a multiplicity of infection (MOI) of 10 before use. In some experiments, *S. aureus* was heat killed (for 30 min at 60°C). After treatment, bacteria were washed three times with phosphate-buffered saline (PBS) prior to use.

**Labeling of the bacteria.** Bacteria (10⁷ ml⁻¹) were washed twice with PBS, suspended in fluorescein isothiocyanate (FITC; 1 μg ml⁻¹; Sigma, Israel) dissolved in PBS, and incubated for 30 min under constant shaking at 37°C. FITC-labeled bacteria were washed three times with PBS prior to use. In some experiments, sulfo-N-hydroxysuccinimide-hexanoeato linker chain–biotin (Perbio Science, Germany) was dissolved at a final concentration of 1 μg ml⁻¹ in PBS. Identical volumes of bacteria in FITC-PBS and biotin were combined and further incubated under the same conditions as those described previously (1).

CBMC. CBMC were obtained by culturing umbilical cord blood mononuclear cells as previously described (3). Briefly, fresh cord blood was diluted with Hank’s balanced salt solution, loaded onto Ficoll-Paque, and centrifuged (350 × g for 25 min). Mononuclear cells were washed twice with Hank’s balanced salt solution and resuspended in 100 ml minimal essential medium alpha (MEM-α) containing 10% (vol/vol) fetal calf serum (FCS), penicillin (100 U ml⁻¹), streptomycin (100 μg ml⁻¹), ribonucleosides/deoxyribonucleosides, and stem cell factor (100 ng ml⁻¹) (a gift from Amgen). Culture medium was replaced weekly. CBMC were used after 8 to 12 weeks of culture, when >97% were positive for tryptase, as assessed by intracellular flow cytometry (1). According to the Institutional Helsinki Committee guidelines of Hadassah Hospital, and its use was approved by the committee.

**Adherence assay.** For quantitative adhesion assays, bacterial suspensions were incubated with CBMC (2.5 × 10⁷ ml⁻¹) in 48-well tissue culture plates (Nunc, Denmark). After incubation periods of 30, 60, 120, and 180 min at 37°C, *S. aureus*-associated CBMC were washed three times with PBS, lysed with 0.1% Triton X-100 in PBS diluted, and cultured onto blood agar at 37°C for 24 h and cultured onto blood agar at 37°C for 24 h before use. The number of intracellular bacteria (IC) was determined by the gentamicin protection assay (34). Briefly, after 180 min of incubation, *S. aureus*-associated cells were washed three times with PBS and subsequently incubated with MEM-α containing gentamicin (300 μg ml⁻¹). The wells were then incubated for 30 min at 37°C and washed three times with PBS. Cell lysis was carried out as described for the quantitative adhesion assay, and the lysates (100 μl) from each well were diluted and plated on blood agar for the determination of viable intracellular bacteria (IC). In preliminary experiments, *S. aureus* strains were tested for gentamicin sensitivity; no colonies were present in blood agar after 180 min of incubation with 300 μg ml⁻¹ of gentamicin in MEM-α medium. The internalization assay also was carried out by flow cytometric analysis (i.e., fluorescein-activated cell sorting [FACS]) (32), and CBMC were incubated with killed or live FITC-labeled *S. aureus*. After 180 min, the *S. aureus*-associated CBMC were washed twice with ice-cold flow buffer (PBS containing 1% FCS) and resuspended in flow buffer. The samples were kept in the dark on ice until the analysis. To eliminate signals from extracellular bacteria, trypan blue solution (0.4%; Sigma, Israel) was added to a final concentration of 0.2% directly before analysis. Samples were analyzed using a Becton-Dickinson FACSCalibur and Cell Quest software. To assess the amount of internalized bacteria, the percentage of FITC-positive cells was multiplied by the mean fluorescence intensity of these cells to obtain the uptake index (i.u.). No toxic effect was detected toward *S. aureus* strains during FITC or biotin labeling. Furthermore, to check the validity of the quenching approach, FITC-labeled *S. aureus* alone with or without trypan blue treatment was analyzed by flow cytometry. In previous experiments, the FITC-labeled *S. aureus* signal was abrogated after trypan blue treatment. To observe intracellular killing or bacterial survival,
the experimental design of the protection antibiotic assay was changed. CBMC were infected with S. aureus for 180 min, and at this point the medium was replaced with MEM-α containing 300 μg ml⁻¹ gentamicin. Instead of analyzing all samples after 30 min of gentamicin treatment, samples were taken out after 30, 60, 120, and 180 min. The number of viable bacteria at 30 min was considered 100%.

Cytochalasin D treatment. To study the role of the cytoskeleton in S. aureus uptake, CBMC were incubated with cytochalasin D (2.5 to 5 μg ml⁻¹; Sigma, Israel) for 60 min at 37°C before S. aureus interaction and also during the entire gentamicin protection assay, as described above. In preliminary experiments, cytochalasin D was assessed for toxicity for both S. aureus strains and CBMC and was found either to have no adverse effects or to change adhesion and invasion properties at concentrations of up to 5 μg ml⁻¹.

CD46- and TLR2-mediated inhibition invasion assay. The involvement of CD46 and TLR2 molecules in CBMC during exposure to S. aureus also was investigated. CBMC were incubated with anti-human CD48 (MEM-102; 10 μg ml⁻¹; Santa Cruz Biotechnology), anti-human TLR2 (clone TLR2.1; 10 μg ml⁻¹; Ebioscience), or isotype-matched IgG1 (MP Biomedicals, Germany) at room temperature for 30 min before the adherence and internalization assays were performed.

Evaluation of cytokine concentration. CBMC suspensions were analyzed for S. aureus-specific IL-8 and TNF-α cytokine production. CBMC were incubated with killed or live S. aureus at different time points at 37°C. The levels of each cytokine in culture supernatants were determined using specific enzyme-linked immunosorbent assay kits according to the manufacturer’s instructions (R&D Systems). The results are expressed as the concentration of cytokine per 10⁶ CBMC, as extrapolated from a standard curve with recombinant cytokine. To define the possible role of S. aureus invasion in IL-8 and TNF-α release, CBMC were treated with cytochalasin D for 60 min before infection. To rule out the possibility that cytochalasin D treatment affected the capacity of CBMC to release IL-8 and TNF-α, cytochalasin D-treated cells (5 μg ml⁻¹) and nontreated cells were incubated with PGN (10 μg ml⁻¹; Sigma, Israel), a well-known TLR2 agonist and cell activator. To study the possible role of TLR2 and CD48 molecules on S. aureus-induced IL-8 and TNF-α release, CBMC were treated with anti-human CD48 (10 μg ml⁻¹), anti-human TLR2 (10 μg ml⁻¹), both antibodies, or isotype-matched IgG1 for 60 min before infection.

Statistical analysis. All assays were performed in triplicate and repeated at least three times. Results are presented as the means ± standard deviations. The Student’s t test or analysis of variance followed by the Tukey-Kramer multiple comparison test were used to compare means, with a P ≤ 0.05 considered statistically significant.

RESULTS

S. aureus invades and survives in CBMC. It has been recognized that adherence to and invasion in host cells are important steps in the pathogenesis of many bacteria, including that of S. aureus (15). As shown in Table 1, S. aureus strains quickly adhered to CBMC (within 30 min). The number of adherent bacteria increased steadily with time similarly for both strains. In fact, at 30 min, 9.86 (strain 25923) and 10.66% (HUH1) of the bacteria adhered to CBMC, whereas at 180 min we found 41.14 and 34.29% adherent bacteria, respectively. To check whether bacterial internalization takes place, CBMC were incubated with biotinylated and FITC-labeled S. aureus. Confocal microscopy clearly differentiated between several small clusters of extracellular bacteria adhering to the CBMC surface and small clusters of intracellular bacteria (Fig. 1). In addition, the antibiotic protection assay detected viable internalized bacteria at 30 min postinfection. The percentage of internalized bacteria increased with time, with a mean of 0.09 and 1.49% for the HUH1 strain and 0.06 and 1.36% for strain 25923 after 30 and 180 min, respectively (Table 1). Furthermore, we compared the internalization of live bacteria to that of heat-killed bacteria by CBMC at 180 min. FACS analysis (Fig. 2) revealed that approximately 60% more S. aureus cells were internalized by CBMC when the bacteria were live than when they were heat killed (u.i., 4.05 × 10⁶ ± 1.3 × 10⁶ for live and 1.69 × 10⁶ ± 0.3 × 10⁶ for heat killed [P < 0.001]). Furthermore, FACS analysis detected approximately 65 and 41% of the cell population with a strong fluorescent signal.
when CBMC were incubated with live or heat-killed *S. aureus*, respectively. Since fluorescence emitted by extracellular bacteria and CBMC-attached bacteria was quenched by trypan blue, this strong fluorescent signal from CBMC suggests the presence of intracellular bacteria.

To assess the role of the cytoskeleton on *S. aureus* internalization by CBMC, the infections were carried out in the presence of cytochalasin D (2.5 and 5 µg ml⁻¹). The data presented in Fig. 3 show that cytochalasin D inhibited *S. aureus* internalization by up to 80% (*P* < 0.001). To evaluate whether intracellular *S. aureus* is killed by CBMC, after 180 min of bacterium-cell interaction, the CBMC were incubated with gentamicin at different time points. Surprisingly, an increase of bacterial survival was found (～57% increase) for both strains after 180 min compared to the percentage of recovered bacteria after 30 min (100% of viable bacteria recovery) (Table 2). This is consistent with an increased survival of bacteria after being internalized by CBMC.

*S. aureus* stimulates TLR2 and CD48 expression on CBMC surface. Uninfected CBMC expressed low levels of TLR2 and CD48 on the cell surface (Fig. 4A, B). However, after infection with *S. aureus*, an increase of TLR2 and CD48 molecule expression on the CBMC surface was detected. The increase of these molecules was evident at 30 min and was augmented at 180 min after *S. aureus* invasion and survival (Fig. 4). Infected CBMC incubated with isotype-matched IgG1 expressed low levels of TLR2 and CD48 that were similar to those expressed by uninfected CMBC. These results indicate that *S. aureus* is capable of upregulating TLR2 and CD48 on CBMC in a time-dependent fashion. To determine whether TLR2 expression induced in response to *S. aureus* is dependent on bacterial viability, CBMC were incubated with killed *S. aureus*. Killed *S. aureus* did not result in the stimulation of TLR2 expression on CBMC (data not shown).

CD48 and TLR2 molecules are involved in *S. aureus* internalization by CBMC. It has been recognized that CD48 and TLR2 are involved in bacterium-mediated cell activation (22, 37). Therefore, CBMC were preincubated with TLR2- and CD48-neutralizing antibodies. As detected by FACS and by the antibiotic protection assay (Fig. 5A, B), anti-TLR2 and anti-CD48 neutralizing antibodies decreased *S. aureus* internalization by CBMC by approximately 40% compared to untreated cells.

### Table 2. *S. aureus* intracellular survival after internalization by CBMC

<table>
<thead>
<tr>
<th>Gentamicin treatment (min)</th>
<th>No. (%) of viable bacteria recovered</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ATCC 25923</td>
</tr>
<tr>
<td>30</td>
<td>1.32 × 10⁵ ± 1.03 × 10⁵ (100)</td>
</tr>
<tr>
<td>60</td>
<td>1.44 × 10⁵ ± 3.21 × 10⁵ (109)</td>
</tr>
<tr>
<td>120</td>
<td>1.63 × 10⁵ ± 2.37 × 10⁵ (124)</td>
</tr>
<tr>
<td>180</td>
<td>1.94 × 10⁵ ± 0.45 × 10⁵ (147)</td>
</tr>
</tbody>
</table>

*a* CBMC (2.5 × 10⁵ ml⁻¹) were incubated with *S. aureus* strains (MOI of 10) for 180 min at 37°C. After infection, CBMC were incubated with gentamicin (300 µg ml⁻¹) for the indicated periods of time, and the number of CFU protected from gentamicin killing was counted (calculated as described in footnote of Table 1). Data are means ± standard deviations from three experiments performed in triplicate.

---

**FIG. 2.** FACS analysis of *S. aureus* internalization. The FACS of CBMC in the presence of trypan blue discriminates cell-associated extracellular bacteria from intracellular bacteria. CBMC were incubated with killed FITC-labeled *S. aureus* (A) or live FITC-labeled *S. aureus* (B) for 180 min at 37°C. After the addition of trypan blue, samples were analyzed by FACS. Data are from a representative experiment (*n* = 3) that depicts the percentage of CBMC intracellular *S. aureus* as well as the percentage of the u.i. M1 is the marker set at approximately 95% of the total events using nonlabeled *S. aureus*.

**FIG. 3.** Cytochalasin D inhibits *S. aureus* invasion of CBMC. CBMC treated with cytochalasin D for 60 min before infection were incubated with *S. aureus* strains (MOI of 10) for 180 min at 37°C, and the percentage of internalized bacteria was evaluated. Results are the means (± standard deviations) from three independent experiments (* and **, *P* < 0.001 compared to results for untreated cells).
S. aureus internalization by nontreated CBMC (for anti-TLR2, $4.38 \times 10^6 \pm 1.4 \times 10^6$ IC for isotype-treated CBMC and $1.53 \times 10^6 \pm 1.7 \times 10^6$ IC for pretreated CBMC; for anti-CD48, $3.72 \times 10^6 \pm 0.3 \times 10^6$ IC for isotype-treated CBMC and $1.62 \times 10^6 \pm 1.8 \times 10^6$ IC for pretreated CBMC [$P < 0.001$]). In contrast, S. aureus adherence was not affected by the neutralizing antibody treatment ($4.25 \times 10^7 \pm 0.2 \times 10^7$ adherent bacteria for non-pretreated CBMC and $4.43 \times 10^7 \pm 1.6 \times 10^7$ adherent bacteria for pretreated CBMC; $P > 0.05\%$) (data not shown).

S. aureus induces IL-8 and TNF-α release by CBMC. The infection of CBMC with S. aureus induced IL-8 and TNF-α release. Time course experiments showed that there was a positive correlation between IL-8 and TNF-α and the duration

---

**FIG. 4.** Invasive S. aureus upregulates TLR2 and CD48 molecules on CBMC. CBMC were incubated in medium or infected with S. aureus (MOI of 10) for 180 min at 37°C. Cells then were stained with anti-TLR2 (A) or anti-CD48 antibody (B) and analyzed by FACS. Noninfected cells are indicated by the shaded areas, and the infected ones are indicated by the white areas. These results are representative of three independent experiments.

---

**FIG. 5.** TLR2 and CD48 receptors are involved in S. aureus uptake by CBMC. CBMC were preincubated with anti-human TLR2 (A) or anti-human CD48 (B) neutralizing antibody before incubation with S. aureus (MOI of 10) for 180 min at 37°C. After infection, cells were incubated with gentamicin for 60 min to kill extracellular bacteria, and the samples were analyzed by FACS. Pretreated CBMC are indicated by the shaded areas in the histograms. These results are representative of three independent experiments.
of *S. aureus*-CBMC interaction (for IL-8, 266.67 ± 11.11 pg at 30 min and 600.96 ± 12.40 pg at 360 min; for TNF-α, 420 ± 14.14 pg at 30 min and 1,145.5 ± 265.06 pg at 360 min [P < 0.001]) (Fig. 6). Furthermore, noninfected CBMC released 200.5 ± 33.23 pg of TNF-α (Fig. 6A) and 150.54 ± 14.53 pg of IL-8 (Fig. 6B) after 360 min of incubation.

To determine whether proinflammatory cytokine release was dependent on bacterial viability, CBMC were incubated with killed *S. aureus*. Killed *S. aureus* preserved the ability to adhere to and trigger IL-8 and TNF-α release from CBMC in a time-dependent manner (for IL-8, 164.51 ± 9.49 pg at 30 min and 401.40 ± 11.38 pg at 360 min; for TNF-α, 450.5 ± 42.42 pg at 30 min and 1,060 ± 155.56 pg at 360 min [P < 0.001]) (Fig. 6).

We next evaluated whether proinflammatory cytokine release was dependent on *S. aureus* uptake. Therefore, the *S. aureus*-CBMC interaction was performed in the presence of cytochalasin D. The results in Fig. 7 show that in this case, IL-8 (Fig. 7A) and TNF-α (Fig. 7B) release was drastically decreased compared to IL-8 and TNF-α release by infected CBMC without cytochalasin D treatment (P < 0.01 and P < 0.001, respectively). The cytochalasin D treatment did not influence the PGN-induced IL-8 and TNF-α release by CBMC, and no synergistic effect was observed when PGN was incubated with infected CBMC (Fig. 7).

We also investigated the role of TLR2 and CD48 molecules on *S. aureus*-induced cytokine release. CBMC were incubated with anti-human TLR2 and anti-human CD48 antibodies or both antibodies before infection (Fig. 8). Anti-TLR2 significantly reduced the IL-8 (Fig. 8A) and TNF-α (Fig. 8B) release by CBMC (P < 0.001). Anti-CD48 also decreased the cytokine release (P < 0.01). Furthermore, the combination of these antibodies had a significant synergistic effect (P < 0.001). The amount of IL-8 and TNF-α released by CBMC incubated with isotype-matched IgG was similar to that of infected cells (for IL-8, 602 ± 32.72 pg and 624.94 ± 45.94 pg; for TNF-α, 787.51 ± 31.14 pg).

DISCUSSION

This study provides, for the first time, evidence of a direct in vitro interaction between bacterial pathogens such as *S. aureus* and human mast cells. In fact, we have demonstrated that human CBMC recognize *S. aureus* and respond to its infection
by releasing proinflammatory cytokines. *S. aureus* displayed a high adherence to, as well as invasive and survival abilities in, the mast cells. FACS analysis showed the percentage of internalized live *S. aureus* to be higher than that of the antibiotic protection assay at the same time point (30%; *P* < 0.01) (data not shown). This can be attributable to differences in bioassays. FACS analysis detects both live and killed internalized bacteria, while the antibiotic protection assay detects only live bacteria (32). FACS analysis also detected the uptake of heated killed *S. aureus*, suggesting that the mast cells have phagocytic ability. Although there are several previous reports indicating that mast cells have the capacity to recognize, phagocytize, and destroy different bacterial species and, thus, play a potentially crucial role in innate immunity (18, 19, 28), in some cases mast cells can be both infected and eventually destroyed by the pathogenic bacteria. Because the percentage of bacterial recovery after 180 min of gentamicin treatment was higher than that after 30 min, it is suggested that internalized *S. aureus* not only survived but also multiplied within the mast cells. To the best of our knowledge, this is the first report showing in vitro *S. aureus* survival and proliferation within human mast cells. In fact, Arock et al. (2) reported an appreciable and time-dependent decrease in the viability of *S. aureus* (CI127 strain) associated with mast cells. This discrepancy may be due to genetic and virulence differences among *S. aureus* strains.

The mechanisms underlying bacterial entry, phagosome maturation, and dissemination include strategies, as well as unique tactics, evolved by individual species to establish infection. Invasive bacteria actively induce their own uptake by phagocytosis in normally nonprofessional phagocytic cells and then either establish a protected niche within which they survive and replicate or disseminate from cell to cell by means of an actin-based motility process. Therefore, the uptake of bacteria by mast cells may account for the virulence of *S. aureus* in diseases, especially those associated with atopy in which there is an increase in mast cell numbers. This organism also may use mast cells to establish inflammatory responses and metastatic foci of infection.

Our data also demonstrate that *S. aureus*-infected mast cells evoke significant IL-8 and TNF-α release. Mast cell-derived TNF-α and IL-8 have been shown to be responsible for neutrophil recruitment. TNF-α is of particular interest, because mast cells are the only known cells to store this cytokine and, thus, are able to release this mediator immediately upon activation (21). Furthermore, the mast cell enhancement of early neutrophil recruitment is considered a potential mechanism of host defense during bacterial infection (20, 21). Therefore, mast cells also may contribute to immunity against *S. aureus* infection through this mechanism. Killed *S. aureus* also was able to trigger proinflammatory cytokine release from the mast cells. There are several reports showing the ability of commercial purified PGN and lipoteichoic acid to induce proinflammatory cytokine release by different types of cells (8, 11, 37, 40). Since heat-killing treatment preserves the integrity of bacteria, it is not surprising that killed *S. aureus* also preserves this ability. These data also suggest that cytokine release by the mast cells does not require an active bacterial infection. This is particularly interesting because during an infection, bacteria can be killed and released from surface molecules, like PGN and lipoteichoic acid, that can activate mast cells and trigger an inflammatory response (8, 10). We can hypothesize that these data are particularly relevant to atopic dermatitis, in which the interactions of mast cells with products from *S. aureus* could be critical in the local enhancement of chronic inflammation at specific skin sites (24). In previous works it was reported that *S. aureus* components may lead to an increase in the release of Th2-related cytokines (4, 42, 48). Specifically, it was shown that PGN may increase the release of IL-5, IL-10, and IL-13 from human mast cells (48). However, the influence of other *S. aureus* components on human mast cell degranulation and Th2-related cytokine synthesis and release requires further study.

Several glycosylphosphatidylinositol-anchored proteins are located in the lipid rafts of the mast cell plasma membrane. CD48 is one protein that has been implicated specifically in bacterial adherence, invasion, and/or bacterium-mediated cell activation (9, 20, 22). Moreover, we have recently shown a selective increase in the expression of CD48 both in human and in murine allergic asthma. Its selective downregulation by the use of CD48-neutralizing antibodies in murine asthma resulted in an amelioration of the disease (29, 30). Taken together, these data suggest an important link between CD48 and bacterial infection and allergy. TLR2 is another important receptor on the mast cells, and it is involved in the recognition of lipoproteins, lipoteichoic acid, and PGN from gram-positive bacteria (40). Our results show that CD48- and TLR2-neutralizing antibodies highly decrease the *S. aureus* internalization by the mast cells, indicating the involvement of these two molecules in *S. aureus* internalization. Furthermore, we found that the *S. aureus* infection upregulated the expression of TLR2 and CD48 on the mast cell surface. Therefore, it is possible to speculate that, in vivo, invasive *S. aureus* could prime mast cells to be more responsive to CD48- and TLR2-specific ligands.

CD48 also has been implicated in *Mycobacterium tuberculosis* internalization by rat peritoneal mast cells and the adherence of FimH-expressing type 1 fimbriated *E. coli* on the mast cell surface (22, 31). In addition, our data are in accordance with recent reports that have demonstrated that *Porphyromonas gingivalis*, *Mycobacterium avium*, and Klebsiella pneumoniae in-
vade endothelial cells, macrophages, and airway epithelial cells as well as upregulate TLR expression and elicit an inflammatory response (33, 45, 47). Interestingly, TLR2 could be involved in S. aureus survival in the mast cells. The reason for this speculation comes from two recent reports showing that S. aureus and P. gingivalis were cleared in TLR2-deficient macrophages more rapidly than in the wild type (6, 46). However, it remains to be clarified whether the TLR2-mediated survival mechanism comes from two recent reports showing that S. aureus infection leads to bacterial persistence and TLR2 deficiency attenuates induced inflammation. Am. J. Pathol. 171:537–547.


33. Regueiro, V., M. A. Campos, J. Pons, S. Alberti, and J. A. Bengoechea. 2006. The uptake of a Klebsiella pneumoniae capsule polysaccharide mutant trig-


Editor: B. A. McCormick